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Identification of small molecule
enzyme inhibitors as broadspectrum anthelmintics
Rahul Tyagi1, Mostafa A. Elfawal2, Scott A. Wildman3, Jon Helander4, Christina A. Bulman5,
Judy Sakanari5, Bruce A. Rosa1, Paul J. Brindley 6, James W. Janetka 4, Raffi V. Aroian2 &
Makedonka Mitreva 1,7
Targeting chokepoint enzymes in metabolic pathways has led to new drugs for cancers, autoimmune
disorders and infectious diseases. This is also a cornerstone approach for discovery and development of
anthelmintics against nematode and flatworm parasites. Here, we performed omics-driven knowledgebased identification of chokepoint enzymes as anthelmintic targets. We prioritized 10 of 186
phylogenetically conserved chokepoint enzymes and undertook a target class repurposing approach
to test and identify new small molecules with broad spectrum anthelmintic activity. First, we identified
and tested 94 commercially available compounds using an in vitro phenotypic assay, and discovered
11 hits that inhibited nematode motility. Based on these findings, we performed chemogenomic
screening and tested 32 additional compounds, identifying 6 more active hits. Overall, 6 intestinal
(single-species), 5 potential pan-intestinal (whipworm and hookworm) and 6 pan-Phylum Nematoda
(intestinal and filarial species) small molecule inhibitors were identified, including multiple azoles,
Tadalafil and Torin-1. The active hit compounds targeted three different target classes in humans, which
are involved in various pathways, including carbohydrate, amino acid and nucleotide metabolism. Last,
using representative inhibitors from each target class, we demonstrated in vivo efficacy characterized
by negative effects on parasite fecundity in hamsters infected with hookworms.
Metabolic potential is a critical determinant for a pathogen’s development and growth, infectivity and maintenance1–5. Consequently, the enzymes comprising the metabolic network of a pathogen are potential targets for
drug discovery. In fact, multiple drugs in current clinical and agricultural use as anti-infective agents target these
enzymes2,3,5. However, this approach has not been suitable for the discovery of anthelmintics until recently, due to
insufficient knowledge regarding the metabolism of parasitic nematodes - partly due to large metabolic diversity
within the phylum, especially amongst those inhabiting distinct trophic niches. Moreover, until recently, there
has also been a lack of a comprehensive knowledgebase of their genomes and biochemistry. This newly generated
genomics information4,6 significantly facilitates and expedites the development of drugs targeting specific parasites, and also enables comparative studies to infer shared similarities in diverse parasites that could be exploited
to design anthelmintics with a broad-spectrum potential. Such anthelmintics are especially desirable because
concomitant infections with different parasites are predominant in endemic countries7–9.
In an earlier study to identify novel broadly effective anthelmintics1, we followed an omics-driven target and
drug prioritization approach to find potential metabolic enzyme drug targets using data from 10 Nematoda
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Figure 1. Flowchart outlining the overall analysis pipeline. ww = ”whipworm”.

genomes, including four parasitic nematodes (a whipworm, a filarial worm, and two plant parasitic species).
The premise of that work was that certain enzymes in the metabolic network form nodes that are especially
vulnerable and hence are attractive candidates for drug-targeting. Specifically, targeting the enzymes that either
uniquely produce or uniquely consume a substrate, called ‘chokepoint enzymes’10 is expected to harm the parasite
by changing the concentration of the substrate to either too low or too high, potentially leading to morbidity or
mortality. If carefully selected, employing insight into the biology and metabolic requirements of both the host
and the pathogen, such targets have the potential to selectively harm the parasites without unacceptable side
effects for the host. Based on the target and hit prioritization, seven compounds were selected and assayed in vitro
in three highly divergent nematodes - C. elegans, a hookworm and a filarial species. Perhexiline, a putative inhibitor of carnitinepalmitoyl transferase (CPT) was effective against all three species. This work formed the basis of
further exploration of putative CPT inhibitors repurposed for their anthelmintic potential11.
One limitation of the previous studies was the small number of nematode genomes available at the time, especially for parasitic worms. Moreover, even among the 10 genomes that were used, five belonged to the free-living
genus Caenorhabditis. Fortunately the total number of nematode genomes and the diversity represented in those
species has substantially increased in recent years, particularly with the publication of a large number of helminth
genomes and their comparative analyses by International Helminth Genomes Consortium (IHGC12). Among the
multiple analyses reported by IHGC was a comparison of the metabolic potential of nematodes, requiring us to
develop a comprehensive method for enzyme annotation, and generate pathway reconstructions13–15, resulting in
novel insights and confirmation of previous results that can be important for drug discovery and for understanding parasite biology and host-parasite interactions. The genomic data now available to us provide an opportunity
to expand upon previous studies using a more representative set of parasitic worms for prioritizing chokepoint
enzymes as drug targets and advancing the chemogenomic analysis, and phenotypic and in vivo assays.
Our primary objective was to identify drugs effective against whipworm and hookworm, which are among the
most important human parasites. Moreover, we also aimed at covering ever broader phylogenetic and physiological range. Therefore, in this study, we strategically selected a set of 17 representative parasitic nematode species,
spanning 4 of the 5 nematode phyla, including both intestinal and filarial worms, and used systems biology and
evolutionary principles to reconstruct metabolic networks for these diverse parasites11,13,15. We were able to carry
out more accurate gene- and single nucleotide-level comparative studies leveraging the recent advancements in
genomic resources and metabolic databases. For instance, comparing a potential target gene among a diverse group
of parasites and with the host gene sequence, critical sequence variations may be identified which are specific to the
parasites, or are highly conserved among nematodes yet sufficiently divergent from the host16. Such omics-driven
knowledge-based target prioritization approach17,18 followed by chemogenomic screening using large-scale drug
databases (e.g. ChEMBL19) facilitated the identification of drug-like compounds with broad-spectrum control
potential. We selected representative intestinal parasites at the extremes of the phylogeny20 (whipworm Trichuris
muris from clade I of Nematoda and hookworm Ancylostoma duodenale from clade V) along with a phylogenetically
distant lymphatic parasite (filarial Brugia pahangi from clade III) to conduct phenotypic screening of adult developmental stages of these worms to validate our predictions. The approach enabled the identification of inhibitors of
key chokepoint enzymes that shared potentially pan-intestinal and pan-phylum efficacy. We also pursued iterative
phenotypic screening guided by structure-activity relationships (SAR) to expand our list of lead compound candidates. The in vivo effect of representative compounds was also tested.

Results and Discussion

Identifying and prioritizing the metabolic enzyme chokepoints in parasitic nematodes.

The
overall analysis process is outlined in Fig. 1 (for more details see Supplementary Fig. S1). A total of 669 unique
ECs (Enzyme Commission IDs) were identified across 17 nematode species. Analysis of individually reconstructed metabolic networks led to identification of 389 ECs that were chokepoints in at least one species
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EC

# of
nematodes
with
chokepoint
(/17)

Chokepoint description

# KEGG
pathways
containing
EC

Sterile/Lethal C.
elegans phenotype

Maximum
A. ceylanicum Stage gene expression
81HG score17
(/137; top
Adult exp.
Adult/Infective
25% of
percentile
ratio percentile
genes)

1.1.1.27

L-lactate dehydrogenase

17

4

—

105

82.5%

86.3%

1.1.1.37

Malate dehydrogenase

17

4

Embryonic lethal

132

93.9%

81.3%

1.2.1.3

Aldehyde dehydrogenase (NAD+)

13

13

—

121

76.0%

62.1%

1.3.5.2

Dihydroorotate dehydrogenase (quinone)

12

1

—

120

60.3%

63.5%

2.7.1.1

Hexokinase

17

5

—

—

60.8%

91.6%

2.7.1.67

1-phosphatidylinositol 4-kinase

13

1

Sterile progeny

120

45.2%

40.1%

2.7.1.33

Pantothenate kinase

16

1

—

120

63.7%

51.9%

3.1.3.11

Fructose-bisphosphatase

15

3

—

105

70.1%

76.6%

3.1.4.17

3′,5′-cyclic-nucleotide phosphodiesterase

17

1

Sterile

123

62.9%

43.0%

3.4.11.1

Leucyl aminopeptidase

17

1

—

—

75.0%

62.1%

Table 1. Characteristics of the top 10 prioritized nematode chokepoint enzymes.

(Supplementary Table S1). Among these, 186 were taxonomically conserved20 across at least Trichuris muris
(Clade I), Ancylostoma ceylanicum (Clade V) (the two species used for screening – “target species”) and at least
one other Clade III or Clade IVa species (to ensure broad nematode conservation).
These 186 chokepoint ECs were ranked based on a weighted scoring method (Supplementary Fig. S1;
Methods) which included phylogenetic conservation, number of metabolic pathways they are involved in, RNAi
phenotype of the C. elegans ortholog, previous identification in literature, and RNAseq based expression levels in
especially relevant developmental stage(s). Every nematode chokepoint from the two target species - intestinal
nematodes representing the phylogenetic extremes of the phylum Nematoda (clade I, the whipworm T. muris
and clade V, the hookworm A. ceylanicum) - was linked to ‘drug-like’ compounds in the ChEMBL19 database
based on similarity to ChEMBL targets, resulting in 448 and 606 unique ChEMBL targets corresponding to 664
A. ceylanicum proteins and 756 T. muris proteins, respectively. Using pChEMBL19 values a total of 188,454 target:compound pairs were identified (pChEMBL score ≥5, corresponding to 10 μM IC50 etc.). Of these, 83,134 pairs
included both a gene with an EC assignment and a compound with a “Quantitative Estimate of Druglikeness”
(weighted QED) score recorded in the database. Intersection of these with the 186 selected nematode chokepoint ECs resulted in 22,498 conserved chokepoint ChEMBL target:compound pairs (82 targets/64 ECs paired
to 12,395 unique compounds). The final ChEMBL target:compound scores were calculated, prioritizing target:chokepoint pairs that have high drug likeness and high target affinity. Multiplying the final nematode chokepoint
EC score and the final ChEMBL target:compound score (Supplementary Fig. S1C) resulted in the final prioritization score. Thereafter, the 22,498 scored compound:target pairs (64 ECs) were reduced to 11,869 pairs (50 ECs)
with a PDB21 (Protein Data Bank) structural match to the target. In the final step, the top 3 target:compound pairs
per EC were selected (142 total target:compound pairs, 128 compounds; Supplementary Fig. S1D, Supplementary
Tables S2, S3), and these were ranked according to the final prioritization score.
Out of the top 50 ECs, 10 ECs were prioritized based on associated compound availability and guided by
literature review of the EC functions and potential for biological efficacy (Table 1). These ECs were categorized
into five classes. The first class of target ECs was dehydrogenases, and included (i) L-lactate dehydrogenase (LDH;
1.1.1.27), previously suggested to be a potential anthelmintic target in Clonorchis sinensis22 and Taenia asiatica23. A wide variety of existing effective anthelmintics including Praziquantel, Levamisole, and Mebendazole
have been found to result in LDH inhibition in trematode family Paramphistomidae24; (ii) Malate dehydrogenase (MDH; 1.1.1.37), inhibited by several major benzimidazole anthelmintics including Albendazole, although
it is not their primary target25; (iii) Aldehyde dehydrogenase (NAD+) (ALDH; 1.2.1.3), previously explored
as a potential target due to its impact on alcohol tolerance and cancer chemotherapy resistance. ALDH may
be related to broad based drug resistance, and its inhibition might facilitate efficacy of other drugs26 and (iv)
Dihydroorotate dehydrogenase (quinone) (DHODH; 1.3.5.2), studied as a target for protozoan (malaria and trypanosome) parasites27–30. The second class of EC targets was kinases, and included (i) Hexokinase (HK; 2.7.1.1),
a possible target of phenothiazine, which had been widely used in the mid-20th century as an anthelmintic31;
(ii) Pantothenate kinase (PanK/CoA; 2.7.1.33), which is involved in CoA biosynthesis and possibly available
at high levels in cells32 and (iii) 1-phosphatidylinositol 4-kinase (PI4K; 2.7.1.67), with several inhibitors under
studies against malaria33 and Cryptosporidium34. The other classes were represented by one EC each, and included
Fructose-bisphosphatase (FBPase; 3.1.3.11), a key enzyme in gluconeogenesis that has not been identified as a target in helminths; 3′,5′-cyclic-nucleotide phosphodiesterase (PDE; 3.1.4.17), inhibitors for which have been suggested to be good potential drugs for targeting parasitic nematodes due to their ability to disrupt the C. elegans life
cycle and nematode-specific active binding sites35; and Leucyl aminopeptidase (LAP-1/cathepsin III; 3.4.11.1), a
potential drug target in Leishmania32, known to be an excretory/secretory (ES) product and a modulator of host
immune system36, and previously studied as a potential vaccine candidate for the liver fluke, Fasciola hepatica37,38.

First generation compound screening with parasitic nematodes in a phenotypic motility assay. To
test the knowledge-based compound predictions for the 10 prioritized ECs (15 ChEMBL targets; 2,167 compound:target pairs; 1,581 drugs), 94 compounds were purchased and assayed in adult hookworm. Eleven (Table 2) had deleterious
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Motility inhibition
Motility index (30uM, 48 hrs) % (30 uM, 48 hrs)
Target

Compound
#

CHEMBL ID

Name or Formula

A. ceylanicum T. muris

B. pahangi (F)

EC#

Descriptor

33

CHEMBL51483

Gossypol

1.5

0.33

22 (83% at day 6)

1.1.1.37

malate dehydrogenase

47

CHEMBL91

Miconazole

0.75

0

95*

1.1.1.37

malate dehydrogenase

58

CHEMBL808

Econazole

0.25

0

99

1.1.1.37

malate dehydrogenase

59

CHEMBL1221

Sulconazole

0

0

99

1.1.1.37

malate dehydrogenase

15

CHEMBL1256459

Torin 1

0.5

0.6

100

2.7.1.67

phosphatidyl-inositol kinase

20

CHEMBL1765602

PP121

1.58

2.42

7 (100 at day 6)

2.7.1.67

phosphatidyl-inositol kinase

30

CHEMBL202740

5-(2-(2-Methoxyphenylamino)thiazol-4-yl)-4methylthiazol-2-amine

1.33

2

44 (100 at day 6)

3.1.4.17

phospho-diesterase

69

CHEMBL203287

4-({[3-cyano-6-(thiophen-2-yl)-4-(trifluoromethyl)
pyridin-2-yl]sulfanyl}methyl)benzoic acid

1.61

0.16

0 (81 at day 6)

3.1.4.17

phospho-diesterase

87

CHEMBL1373924

N-(1,3-benzothiazol-2-yl)-3-methoxybenzamide

1.5

3

N/A

1.3.5.2

dihydroorotate
dehydrogenase

9

CHEMBL474626

N-(4-methyl-1,3-thiazol-2-yl)-3 phenoxybenzamide

1.92**

1.67**

N/A

2.7.1.1

hexokinase

CHEMBL3410400

3-{4,6-dimethyl-3,7,8,10-tetraazatricyclo[7.4.0.02.7]
trideca-1,3,5,8,10,12-hexaen-5-yl}-N-(4acetamidophenyl)propanamide

1.67

2.75

N/A

2.7.1.33

pantothenate kinase

4

Table 2. Compound efficacies in a phenotypic whole worm assay. * - Miconazole tested at 10 uM, not at 30 uM.
** - Worms looked very sick).
effects in hookworm (Motility Index, MI ≤0.75 for severe phenotype, 0.76 to 1.8 for moderate phenotype or had noticeable phenotype; 1.81 to 3, no phenotype) and were putatively targeting six of the 10 enzymes (success rate of 60% based
on the target numbers), representing 3 different enzyme classes (2 dehydrogenases, 3 kinases, and a phosphodiesterase;
Table 2). The 11 compounds causing severe or moderate phenotype in hookworm were also assayed in whipworm
and seven were hits (i.e. had moderate to severe motility inhibition), hence classified as potential pan-intestinal compounds. Four of the seven compounds were potential pan-intestinal hits resulting in severe phenotypes (MI < 1.3) in
both species, and two (33 and 69) had severe phenotype only in whipworm. One compound (9) showed moderate/
noticeable phenotype in both species. Based on our analysis (Supplementary Fig. S1) the active compounds were linked
to drug-like compounds shown to target MDH, PDE and PI4K/PI3K/mTOR in other species. The eight compounds
(out of the 11 hits) associated with these enzymes (Table 2) were screened in non-intestinal nematode, adult stage of the
filarial nematode Brugia pahangi, to examine their pan-phylum potential. Four (15, 47, 58, 59) were effective at day 2,
and 3 additional (20, 30, 33) at day 6 in B. pahangi, hence showing pan-Nematoda potential (motility inhibition of at
least 80% at day 2 or day 5 was used as a cut-off for activity).

Identification of second generation compounds with pan-phylum potential and screening with
parasitic nematodes in a phenotypic motility assay. Based on the results from the 94 first genera-

tion compounds we identified three effective target classes - MDH, PDE and PI4K/PI3K/mTOR - and expanded
the compound list by structural similarity and pharmacophore searches, resulting in identification and screening of 26 second generation compounds (Supplementary Table S4). This compound expansion and screening
in the intestinal and filarial species led to the identification of four (102, 105, 108, 113) further active potential pan-intestinal molecules, of which two (102 and 105) have pan-Phylum molecules (Fig. 2, Supplementary
Table S4) in this series. The putative target-associated compounds that were not active in this assay, were not
necessarily structurally related to the first-generation inhibitors.
Overall the screening of the first and second generation compounds resulted in identification of twelve active
compounds that putatively target three homologous therapeutic targets - MDH, PI3K/mTOR and PDEs (Table 3)
in at least one parasitic species.

Screening of known azoles. Four of our active first-generation compounds were prioritized based on their

known activities against MDH39,40 although they have numerous discrete canonical targets (Table 3). Gossypol
is a polyphenol known to target lactate dehydrogenase41,42 and BCL2 family proteins involved in apoptosis and
APE-1, which participates in DNA damage repair43–45. The other three were azoles (Miconazole, Econazole and
Sulconazole), which are imidazole derivatives known to be antifungal agents. They inhibit P-gp and multiple CYP
proteins. One of the CYP proteins (14 alpha-demethylase) is thought to be the main target that leads to antifungal
activity by inhibiting synthesis of ergosterol, an important steroid necessary for permeability of the fungal cellular
membrane46,47. These azoles also display other activities, including inhibition of certain ion channels and receptors48,49. We included Butaconazole, also an azole, among our second-generation compounds based on the successful motility inhibition shown by these three azoles. Like the other three azoles, Butaconazole is also predicted
to inhibit 14 alpha-demethylase48. In our in vitro assays, Sulconazole had IC50s of 11.8 µM against the whipworm
T. muris and 4.6 µM against the filarial worm B. pahangi.

Screening of known PI3K, PI4K lipid kinases and mTOR inhibitors. Our discovery that the mixed

mTOR/PI3K/PI4K inhibitor Torin1 (15) showed efficacy in inhibiting worm motility in both hookworms and
whipworms prompted us to test other known and more selective inhibitors of each of these kinases. The high
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Figure 2. Structural similarity of the 17 active compounds, identified in the primary, secondary and tertiary
screen of compounds for the identified targets. The clustering was based on (1 − Tanimoto similarity measure)
as distance metric, calculated using ChemmineR105 package, and agglomerated using “complete linkage”
method.

Comp. #

CHEMBL ID

Common name

Literature target

33

CHEMBL51483

Gossypol

LDH49, MD50, BLC2L151, MCL-152,
APE153

47

CHEMBL91

Miconazole

58

CHEMBL808

Econazole

59

CHEMBL1221

Sulconazole

102

CHEMBL1200398

Butaconazole Nitrate

15

CHEMBL1256459

Torin 1

mTOR/PI3K/other kinases59

105

CHEMBL1236962

Omipalisib

PI3K/mTOR60

113

CHMEBL561708

WYE-354

mTOR/PI3K61

30

CHEMBL202740

—

PDE1/PDE566

69

CHEMBL203287

—

PDE1/PDE566

108

CHEMBL779

Tadalafil

PDE5/PDE1167

14alpha-demethylase; certain ion
channels and receptors54–57, MDH48

Table 3. First and second generation active compounds and their targets in literature.

prioritization score of 15 was based on its high potency as an inhibitor of mTOR with an IC50 of 2 nM and 10 nM
in the protein complexes mTORC1 and mTORC2, respectively50. In the same study, it exhibited 1000-fold selectivity of mTOR over PI3K in mammalian cells. In our assays, the IC50 for 15 was 13.3 µM in the whipworm T.
muris and 3.9 µM in the filarial worm B. pahangi. Intriguingly, the structurally related inhibitor Torin-2 (23) did
not exhibit similar activity, nor did the other PI4K kinase inhibitors (95, 106, 109, 116, and 120) (Supplementary
Table S4). Therefore, we identified and evaluated additional mTOR inhibitors and found that Omipalisib51 (105)
and WYE-35452 (113) showed equivalent or better activity against both these nematodes (Fig. 2). Interestingly,
105 showed better activity than 113, a more selective inhibitor of mTOR. Because the structurally related inhibitor Torin-2 did not exhibit activity and Omipalisib did, we screened more selective PI3K inhibitors and additional
mTOR inhibitors to help better indicate the mechanism of action (Supplementary Fig. S3). The three additional
drugs were: 1. CC-223 (124): a potent, selective, and orally bioavailable mTOR inhibitor with IC50 of 16 nM,
>200-fold selectivity over the related PI3K-α53, 2. MLN1117 (Serabelisib; 125): selective p110α (a PI3K) inhibitor with an IC50 of 15 nM54, and 3. XL388 (126): a highly potent ATP-competitive mTOR inhibitor with an IC50
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of 9.9 nM55 which simultaneously inhibits both mTORC1 and mTORC2. None of the three showed significant
activity. Dual inhibitors such as PF-04979064 exist56 and testing them can provide further clarification.

Screening of known PDE inhibitors. We identified a weak PDE1/PDE5 inhibitor (69) (IC50 1.9 µM/0.7 µM
respectively57) in the worm assays and, subsequently, a more potent inhibitor Tadalafil58 (108) among the
second-generation compounds. The additional seven PDE inhibitors tested (Supplementary Table S4) are from
several chemical series, which encompass varied PDE family selectivity profiles. Intriguingly, Tadalafil was the
most active PDE inhibitor, while other classes including Sildenafil (110) and Vardenafil (89) did not show activity against the representative hookworm or whipworm (Supplementary Table S4). The compounds we tested
so far are largely selective for PDE5, PDE1 and PDE6 although our lead Tadalafil also shows significant activity
for PDE11 (IC50 15 nM)59, for which a direct ortholog is not found in nematodes even though PDE5 is the most
closely related nematode enzyme to mammalian PDE11s (Supplementary Fig. S4). Tadalafil is a PDE5 inhibitor with IC50 of 9.4 nM and was at least 1000 times more selective for PDE5 than most of the other families
of PDEs, with the exception of PDE1158. Subsequent screening of BC-11-38 (123), a selective PDE11 inhibitor60, showed no activity against whipworm (Supplementary Table S4). To further explore the Tadalafil scaffold, and to test the hypothesis that we are hitting PDE (and that worm PDE is similar to human), Tadalafil and
N-cyclopropyl Tadalafil were docked into A. ceylanicum PDE5 homology model (Tadalafil docking shown in
Fig. 3a). Acknowledging that uptake may be differentiated, we chose two compounds N-Desmethyl Tadalafil
(121) and N-Desmethyl N-cyclopentyl Tadalafil (122) with varying ClogP (1.864 and 3.7944, respectively) for
screening in whipworm. Both compounds showed activity (Supplementary Table S4). We note that most of the
residues important for interactions with Tadalafil are conserved among Nematoda, but are divergent from the
hosts (Fig. 3b). Additional studies are needed to determine the target, in light of the difference in PDE geneset
among species (e.g. lack of PDE5 and two additional PDE2 in whipworm; Supplementary Fig. S4) and the PDE
expression profiles in adult worms (Fig. 3c; Supplementary Table S5). Both 69 and 108 were not active against the
filarial nematode B. pahangi. Taxonomically restricted residues in PDE5 exist among intestinal and filarial nematodes (Fig. 3c) and further focused studies are needed to determine their role in the observed differential activity.
Putative nematode targets are involved in diverse metabolic pathways. The compounds that
caused the most severe phenotypes putatively target three nematode enzymes that are involved in six metabolic
pathways. PIK (EC2.7.1.67) and PDE (EC3.1.4.17) are involved in inositol phosphate metabolism and purine
metabolism, respectively and MDH (EC1.1.1.37) is involved in four other pathways (described below).
PIK is a transferase that transfers phosphorus-containing groups (phosphotransferases with an alcohol group
as acceptor) which is involved in carbohydrate metabolism (inositol phosphate metabolism). A previous study
has identified another enzyme in the inositol phosphate metabolism pathway, inositol polyphosphate multikinase
(IPMK, EC2.7.1.151), as a druggable and lethal target in kinetoplastid parasites61, showing vulnerability of this
pathway in other parasites.
PDEs are hydrolases that cleave ester bonds (phosphoric-diester hydrolases) and are involved in purine
nucleotide metabolism. Despite the widespread notion that nematodes cannot synthesize purines62, complete or near-complete purine synthesis pathways were recently found in most members of clades I, IIIb
(Ascaridomorpha) and V12. This critical function highlights purine metabolism as a promising drug target, as
evidenced here by the efficacy of targeting PDE; notably, inhibitors of PDE have been suggested as promising
potential drugs against parasitic nematodes given their ability to disrupt the C. elegans life cycle and existence of
nematode-specific active binding sites35. Ten other high priority chokepoints are part of the purine metabolism
pathway (Supplementary Table S6). For example, previously we have prioritized pyruvate kinase (EC 2.7.1.40), an
enzyme upstream of PDE, as a top promising conserved chokepoint drug target,1 and due to its critical function
and diversification in the active site compared to the human host it has also been identified as a promising drug
target for malaria63 and Staphylococcus aureus64. Pyruvate kinase is also a chokepoint in pyruvate metabolism
pathway.
MDH is an oxidoreductase that acts on the CH-OH group of donors with NAD+ as acceptor. It is involved in
three carbohydrate metabolism pathways (pyruvate, glyoxylate/dicarboxylate, and TCA cycle) and also in amino
acid metabolism (cysteine and methionine). It is essential to energy production through both aerobic and anerobic pathways, making it essential for parasite’s survival even in very diverse niches. Some anthelmintics appear
to target MDH activity65 and it was originally thought to be the possible target of benzimidazole anthelmintics,
with Mebendazole shown to inhibit MDH activity in vitro66. Multiple enzymes from carbohydrate metbolism and
glycolytic pathways, including MDH, have been studied for their potential as anthelmintic targets67–69. There are
7 other enzymes among our top 50 chokepoints list (Supplementary Table S2) that are also part of pathways that
involve MDH (4 in pyruvate metabolism and 4 in cysteine/methionine metabolism; one enzyme - EC 1.1.1.27 - is
involved in both these pathways). Many of these have been suggested and explored as potential anti-parasitic,
antifungal or anthelmintic drugs63,70–80.
In vivo efficacy of lead compounds. To ascertain whether the newly discovered classes of pan-nematode

chokepoint inhibitors possessed therapeutic utility in parasitic nematodes, Syrian hamsters (Mesocricetus auratus) infected with A. ceylanicum were treated with representative drugs from each of the three target classes at
100 mg/kg per os, based on previously reported effective dosage of currently used major anthelmintics81. Three
(Butaconazole, Tadalafil and Torin-1) of the four tested compounds that were active in vitro had significant and
noteworthy impact on eggs per gram of feces indicating treatment affected parasite fecundity, although the treatment had no marked effect on worm burden (Fig. 4a,b). Rolipram, a drug that was not active in vitro, did not have
an impact on eggs per gram or on worm burden (Fig. 4c,d).
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Figure 3. Characterizing PDE as a potential target (a) Tadalafil docked to human (magenta) and A. ceylanicum
(cyan) PDE5 homology model, showing the interacting residues. (b) Sequence alignment of PDE5 homologs
from 6 worms (Ac = A. ceylanicum, Na = N. americanus, Ce = C. elegans, Bm = B. malayi, Ov = O. volvulus,
Wb = W. bancrofti) and 3 paralogs each from the hosts human (Hs) and mouse (Mm). No homolog was
identified in T. muris. The region shown here is selected to illustrate that most of the interacting residues
from panel A are conserved among nematodes and divergent from host species (indicated with red asterisks).
Residues at or near the active site that are different between filarial and non-filarial worms are highlighted with
a black asterisk. The residue numbers are based on A. ceylanicum PDE5. The residues matching the aligned
residue in A. ceylanicum are colored, with the color depicting the residue type. (c) A maximum-likelihood
phylogenetic tree based on sequence similarity of PDEs present in A. ceylanicum, T. muris and C. elegans, and
their expression levels in adult stages (FPKM – fragments per kilobase per million mapped reads - plotted as
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bars in the outer track). PDE family clusters are indicated using shaded ellipses. The sequences were aligned
using MAFFT106. The phylogenetic tree is estimated using PhyML 3.0107 and the node support values are
calculated using “aLRT SH-like” option. All node support values are >=0.79.

In conclusion, omics-driven knowledge-based identification of drug targets is a powerful approach to identify
targets essential for organisms survival. Undertaking this approach we were able to prioritize 10 of the 186 identified conserved chokepoint enzymes and undertake a target class repurposing approach to test and identify drugs
with broad spectrum anthelmintic activity. First, we tested 94 compounds using an in vitro phenotypic assay, and
identified 11 actives. Based on the findings and SAR, we tested 32 additional compounds, identifying 6 more
actives. Among the 17 actives 5 are potential pan-intestinal and 6 are potential pan-Nematoda drugs. The active
compounds target three different target classes. Using representative drugs from each target class, we demonstrated efficacy in hamsters infected with hookworm, as characterized by negative effects on parasite fecundity.
While the leading scaffolds require optimization, the study identified target classes and essential pathways for
parasitic nematode survival.

Materials and Methods

Enzyme annotation, nematode chokepoints identification and taxonomic classification. High
confidence annotation of nematode metabolic enzymes was performed as described12. In short, the multi-step process assigns Enzyme Commission (EC) numbers to sequences in proteomes of interest. Multiple
EC-annotation approaches that were employed included KAAS82, PRIAM83, DETECTv284 and BRENDA85. For
species with good quality draft genomes (including the representative intestinal species, T. muris and A. ceylanicum), the pathway hole-filling algorithm of the Pathway Tools package86 was used to identify additional metabolic
enzymes.
Identification and prioritization of nematode chokepoint targets and drug. For nematode choke-

point EC prioritization we first quantified pan-Nematoda chokepoint conservation by performing chokepoint
analysis on 17 species spanning the phylum (Supplementary Fig. S1 and Supplementary Table S1): Ancylostoma
ceylanicum87, Ancylostoma duodenale12, Ascaris lumbricoides12, Ascaris suum88, Brugia malayi89, Dirofilaria
immitis90, Heligmosomoides bakeri12, Loa loa91, Necator americanus92, Nippostrongylus brasiliensis12, Onchocerca
volvulus87, Strongyloides ratti93, Strongyloides stercoralis93, Trichuris muris94, Trichuris suis12, Trichuris trichiura94,
and Wuchereria bancrofti12. Second, chokepoint ECs were assigned a score with a maximum value of 6, based on
five different criteria: (i) ECs with higher levels of pan-Nematoda conservation received a higher score, calculated
using (2× [Number of species/17]), with a maximum value of 2; (ii) Chokepoints annotated to multiple KEGG95
pathways received a higher score, calculated using (number of pathways/4), to a maximum value of 1; (iii) If the
C. elegans ortholog has a “lethal” or “sterile” phenotype annotated by WormBase96, it received 1 point; (iv) The
chokepoints among the top 25% targets scored in the “Comparative genomics of the major parasitic worms” study
(International Helminth Genomes Consortium12) received a score calculated by (score/137), maximum value 1.
This score was based on multiple factors, including lack of human homolog, presence of a C. elegans or Drosophila
melanogaster homolog with a deleterious phenotype, expression in key life cycle stages, widespread conservation
among helminths, lack of paralogs, presence of a related structure in PDB, etc. The top quartile among all the
scored proteins were given a positive score by us, as they represented potentially good anthelmintic targets; and
(v) RNA-Seq-based gene expression levels were used to prioritize ECs based on data from A. ceylanicum (0.5 x the
percentile of the EC’s adult-stage expression compared to all other genes) and T. muris (0.5 x the percentile of the
EC’s [adult stage/free-living larval stages] fold change value compared to all other genes), with a maximum value
of 1. The distribution of all of the contributing scores and the final scores are shown in Supplementary Fig. S2.
For the ChEMBL target:drug pair prioritization, ChEMBL19 targets were annotated among the two target
species (minimum 40% identity across 75% of the protein’s length, P ≤ 10−10) and subsequently ChEMBL was
used to match drugs, identifying target:drug pairs with a pChEMBL score ≥5. The drugs that had a “Quantitative
Estimate of Druglikeness” (weighted QED) score available and were associated with one of the prioritized 186
nematode metabolic chokepoints were identified. The final ChEMBL target:drug scores were calculated by multiplying (i) the pChEMBL drug:target affinity scores, scaled between 0.5 and 1, and (ii) the weighted QED scores,
scaled between 0 and 1. Final prioritization score was calculated by multiplying the final nematode chokepoint
EC score and the final ChEMBL target:drug score (Supplementary Fig. S1). Last, significant sequence similarity
to either a human or a mouse protein with a structure in PDB (sequence match with an E value < 10−10) was
required for a drug:target pair to be included for further consideration.
For each of the 50 target ECs with available PDB structure, the nematode sequence was aligned with that of the
PDB structure using MOE (Chemical Computing Group, Inc.). A two-step visual inspection of the ligand binding
site ranked targets based on (i) identification of a ‘druggable’ binding site97, with compound bound where possible, and (ii) protein sequence differences between the nematode and host sequences in the region of the binding
site (this step was preceeded by manual improvement of the nematode gene models guided by transcriptional
evidence). This process resulted in 10 priority targets.

Identification of small molecule inhibitors. First generation compounds: For the 10 prioritized EC tar-

gets, we identified all reported active compounds in ChEMBL. These were assessed for drug-likeness; PAINS98
were eliminated. Of these, 94 compounds were available for purchase. Both hookworm and whipworm assays
were carried out for an initial batch of 30 compounds. Based on the results of these, it was decided to employ a
stepwise approach for the remaining first generation compounds i.e. hookworm, then whipworm, then Brugia,
contingent on activity in the previous step(s). Second generation compounds: Based on the results from 94 first
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Figure 4. Butaconazole, Tadalafil, Torin-1 reduced fecal egg count but not total worm load and rolipram did
not reduce either fecal egg count or total worm load. (a) Treatment with each of the three drugs significantly
reduced fecal egg count in Syrian hamsters infected with the hookworm A. ceylanicum compared with untreated
control animals. (b) The fecal egg count reduction was not accompanied by a reduction of worm load, which
was not statistically significant between control and treated animals. No reduction in fecal egg count (c) or
worm burden (d) in Syrian hamsters infected with the hookworm A. ceylanicum when treated with rolipram
compared to control animals.

generation compounds, five proteins were reasoned as the potential biologically relevant targets for our active hits
and thus more readily commercially available compounds known to target each of these were included (n = 26).
These were five PI4K/PI3K inhibitors, nine mTOR inhibitors, five PDE inhibitors, two potential malate dehydrogenase inhibitors, and five Econazole analogs. The mTOR inhibitors were included based on CHEMBL1256459
(Torin1) - a potent inhibitor of mTORC1/2. Third generation compounds: Based on the results from the 26 second generation compound, additional compounds were identified and screened (n = 6). These included three
PDE inhibitors, two mTOR and one PI3K (p110α) inhibitor.

Compound screening with adult stage of intestinal nematode Ancylostoma ceylanicum.

In
vitro assays were carried out as described81. Briefly, young adult A. ceylanicum were harvested from the small
intestine of infected hamsters on day 11 post-inoculation (p.i.) and washed three times using prewarmed medium
(RPMI1640, 100 U penicillin, 100 μg/ml streptomycin, 10 μg/ml amphotericin). Three worms were manually
picked into each well of the 96-well, 4 wells/test drug, containing 99 μl of medium. 1 μl of 3 mM (100% DMSO)
drugs were transferred into the corresponding well giving a final concentration of 30 µM (1% DMSO) and 100 µl
final volume. Assay plates were incubated for 48 hours at 37 °C and 5% CO2. Drug activity was determined every
24 hours using the standard motility index. Motility index of 3 were given to vigorous worms, 2 for motile worms,
1 for motile after stimulation by touching and 0 for dead worms. Pyrantel pamoate 30 µM was used as positive
control prepared exactly as the test drugs, while 1% DMSO was used as negative control.

Compound screening with adult stage of intestinal nematode Trichuris muris.

In vitro assays
were carried out as described81. Briefly, T. muris adult whipworms were harvested from the cecum and large
intestines of infected STAT6 −/− mice. Three worms were manually picked into each well of a 24-well plate, 2
wells/ test drug, containing 990 µl. 10 µl of 3 mM (100% DMSO) drugs were transferred into the corresponding
well giving a final concentration of 30 µM (1% DMSO) and a final volume of 1 ml of medium. Test plates were
incubated for 48 hours at 37 °C and 5% CO2. Drug activity was assayed using the standard motility index as per
hookworm adults. Levamisole 30 µM was used as positive control prepared exactly as the test drugs, while 1%
DMSO was used as negative control. IC50 values at 48 hours were established using a non-linear regression with
Prism 7 (Graphpad, La Jolla, CA). Only IC50s displaying R2 values ≥ 0.7 are reported.

Compound screening with adult stage of the filarial nematode Brugia pahangi.

Adult female
B. pahangi worms were obtained from Dr. Brenda Beerntsen, University of Missouri, Columbia, MO. Individual
females were placed in each well of a 24-well plate in culture medium (RPMI-1640 with 25 mM HEPES, 2.0 g/L
NaHCO3, 5% heat inactivated FBS, and 1X Antibiotic/Antimycotic solution.
Initial screening of the compounds was performed at 10 μM for Miconazole, Econazole, and Sulconazole.
Gossypol, Torin2, PP121, and Torin1 were initially screened at 30 μM and 10 μM. Four worms were used as
replicates at each concentration in 500 uL of media. Worms treated only with 1% DMSO served as the negative
control. The cultures were maintained at 37 °C, 5% CO2 incubator for seven days - the duration of the assay.
The Worminator, a visual imaging software, was used to determine the effect of each treatment on worm
motility99. Movements of individual worms were calculated by determining the number of pixels displaced per
second per well. Worm movements were averaged over the time of recording (60 seconds) and mean movement
units (MMUs) were determined for individual worms. Percent inhibition of motility was calculated by dividing
the MMUs of the treated worms by the average MMUs of the 1% DMSO treated control worms, subtracting the
value from 1.0, flooring the values to zero and multiplying by 100%. Videos of the worms during the assay were
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recorded on days 0, 1, 2, 3, and 6 of the incubation. Compounds showing ≥ 75% inhibition of motility at either
concentration on day 3 of the assay were investigated further to determine IC50s. Worms were treated in the same
fashion as above and motility was measured each day for three days using the Worminator. IC50 values on day 3
(Torin 1 and Sulconazole) were established using a non-linear regression curve fit with Prism 7 (Graphpad, La
Jolla, CA). All IC50s with R2 values ≥ 0.7 are reported.

In vivo A. ceylanicum assay.

Assays were conducted essentially as previously81,100. Briefly, 5 weeks old
golden Syrian hamsters were infected with 120 third-stage larvae of A. ceylanicum. Infected rodents were grouped
based on the fecal egg count on day 18 p.i. Each group had five hamsters. Drugs were delivered in water suspension after completely dissolved in 100% DMSO giving a final dose of 100 mg/kg and 0.1% DMSO volume to body
weight. Control group was dosed only with water and 0.1% DMSO. Fecal samples were collected 21 days p.i. for
fecal egg counts. On day 22 p.i., the hamsters were euthanized, and the small intestine was opened longitudinally.
Adult parasites within the intestine were counted under a dissecting microscope.
A 100 mg/kg dosing for in vivo experiments was chosen based on similar studies from other groups as maximum single dosing for anthelmintic compounds81,101–103. For comparison, with current clinically approved
anthelmintics high efficacy is seen with doses at 5–10 mg/kg103,104.

Ethics statement. All animal experiments were carried out under protocols approved by University of
Massachusetts Medical School (UMMS; A-2483 and A-2484) Institutional Animal Care and Use Committees
(IACUC). All housing and care of laboratory animals conformed to the National Institutes of Health (NIH) Guide
for the Care and Use of Laboratory Animals in Research (see 18-F22) and all requirements and all regulations
issued by the United States Department of Agriculture (USDA), including regulations implementing the Animal
Welfare Act (P.L. 89–544) as amended (see 18-F23). Euthanasia was accomplished by CO2 asphyxiation, followed
by bilateral pneumothorax.

Data Availability

The datasets generated during and/or analysed during the current study are available from the corresponding
author on reasonable request.
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